EA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial

EA2197: Optimal Perioperative Therapy For Incidental Gallbladder Cancer (OPT-IN): A Randomized Phase II/III Trial

Brief description of study

This phase II/III trial compares the effect of adding chemotherapy before and after surgery versus after surgery alone (usual treatment) in treating patients with stage II-III gallbladder cancer. This study will determine whether giving chemotherapy before surgery increases the length of time before the cancer may return and whether it will increase a patient's life span compared to the usual approach.

Penn Medicine patients who have recently been diagnosed with gallbladder cancer, that was found after the gallbladder was removed during surgery, will be invited to participate.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Gallbladder Cancer
  • Age: Between 18 Years - 99 Years
  • Gender: All


Updated on 09 Mar 2024. Study ID: 850645
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center